Global menu

Our global pages

Close

Personalised medicine and molecular diagnostics

On 13 October The British Embassy will hold a conference entitled “Personalised medicine and molecular diagnostics: cornerstones of modern oncology”. Wierzbowski Eversheds and AstraZeneca are partners of this event. 

• Progress and challenges in personalised medicine 
• Systemic solutions enabling the development of personalised medicine in the UK?
• Best practice in the United Kingdom: Transferring cutting-edge technology into the clinic
• Best Practice in Poland: Integrating Molecular Diagnostics into Clinical Practice
The aim of this half-day event at the British Embassy is to present UK best practice in the area of personalised medicine, and to discuss how to implement such solutions into Polish oncology. The conference will show how the perception of oncological therapy is changing, and will identify the key challenges that healthcare faces due to the change. Effective introduction of molecular diagnostics and goal-oriented therapy do not only mean modern technology transfer but, above all, they require systemic solutions to integrated approach toward patient and therapeutic decisions.
One of the invited speakers are Marta Gadomska-Gołąb, senior associate, head of Life Sciences at Wierzbowski Eversheds, and Gerard Karp, partner, head of TMT at Wierzbowski Eversheds. They will give a presentation entitled “Personalised Medicine and molecular diagnostics – legal perspective and Big Data”.
Guests of honour during the conference will be Prof. Rory Shaw, medical director at Healthcare UK and Dr Wojciech Niedźwiedź from Weatherall Institute of Molecular Medicine, Oxford University, who will share UK’s experience in the field of personalised medicine.
This event will be of particular interest to representatives of the public sector, institutions responsible for ensuring safe therapy, healthcare providers, patients' organisations, representatives of pharmaceutical and health technology companies.
Full simultaneous translation will be provided. Participation is free to registered delegates.
Find out more about the agenda and registration.

The conference program will cover the following issues:

  • Progress and challenges in personalised medicine 
  • Systemic solutions enabling the development of personalised medicine in the UK?
  • Best practice in the United Kingdom: Transferring cutting-edge technology into the clinic
  • Best Practice in Poland: Integrating Molecular Diagnostics into Clinical Practice
The aim of this half-day event at the British Embassy is to present UK best practice in the area of personalised medicine, and to discuss how to implement such solutions into Polish oncology. The conference will show how the perception of oncological therapy is changing, and will identify the key challenges that healthcare faces due to the change. 

Two of our lawyers were invited to be speakers: Marta Gadomska-Gołąb, head of Life Sciences at Wierzbowski Eversheds, and Gerard Karp, head of TMT at Wierzbowski Eversheds. They will give a presentation entitled “Personalised Medicine and molecular diagnostics – legal perspective and Big Data”.

Guests of honour during the conference will be Prof. Rory Shaw, medical director at Healthcare UK and Dr Wojciech Niedźwiedź from Weatherall Institute of Molecular Medicine, Oxford University, who will share UK’s experience in the field of personalised medicine.

This event will be of particular interest to representatives of the public sector, institutions responsible for ensuring safe therapy, healthcare providers, patients' organisations, representatives of pharmaceutical and health technology companies.

Full simultaneous translation will be provided. Participation is free to registered delegates.


 

Print Friendly and PDF

© Eversheds Sutherland 2021. All rights reserved. Eversheds Sutherland is a global provider of legal and other services operating through various separate and distinct legal entities.

Eversheds Sutherland is the name and brand under which the members of Eversheds Sutherland Limited (Eversheds Sutherland (International) LLP and Eversheds Sutherland (US) LLP) and their respective controlled, managed and affiliated firms and the members of Eversheds Sutherland (Europe) Limited (each an "Eversheds Sutherland Entity" and together the "Eversheds Sutherland Entities") provide legal or other services to clients around the world. Eversheds Sutherland Entities are constituted and regulated in accordance with relevant local regulatory and legal requirements and operate in accordance with their locally registered names. The use of the name Eversheds Sutherland, is for description purposes only and does not imply that the Eversheds Sutherland Entities are in a partnership or are part of a global LLP. The responsibility for the provision of services to the client is defined in the terms of engagement between the instructed firm and the client.